TScan Therapeutics, Inc. (TCRX) earnings
TCRX earnings moved a median of +1.02% by the close. Quarterly and annual TCRX reports and results, each read against the price at its own news timestamp. Back to the TCRX overview →
22 measured TCRX earnings events.
Where these TCRX earnings landedvs 20 measured TCRX earnings reactions
| Middle 50% of TCRX earnings reactions | -3.18% to +4.48% |
|---|---|
| Median reaction (to close) | +1.02% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 TCRX earnings events with a measured close landed between -3.18% and +4.48%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.92% | -2.28% | |
| TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -3.92% | -2.28% | |
| Form 10-Q TScan Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.94% | +5.04% | |
| TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +2.94% | +5.04% | |
| Form 10-K TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.91% | +2.86% | |
| Form 10-Q TScan Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.01% | -2.46% | |
| TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.01% | -2.46% | |
| Form 10-Q TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.62% | — | |
| TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.62% | — | |
| Form 10-Q TScan Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.91% | -7.48% | |
| TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.91% | -7.48% | |
| Form 10-K TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.70% | -5.88% | |
| Form 10-Q TScan Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.26% | -5.33% | |
| TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.43% | -5.74% | |
| Form 10-Q TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.95% | +6.57% | |
| TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.95% | +6.57% | |
| Form 10-Q TScan Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.98% | +4.30% | |
| TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.98% | +4.30% | |
| Form 10-K/A TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.82% | |
| Form 10-K TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +5.15% | |
| Form 10-Q TScan Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +4.57% | +3.61% | |
| TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +4.57% | +3.61% |
Keep exploring
More TCRX: analyst actions → · SEC filings → · TCRX overview →